Cat. No. 1697
Chemical Name: (3S)-6,7-Dimethoxy-3-[(5R)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-1(3H)-isobenzofuranone hydrochloride
Biological ActivityOpioid alkaloid with several actions. Binds to tubulin, arrests cells in mitosis and induces apoptosis. Antagonist at bradykinin receptors (pA2 = 6.68), inhibits carbachol-stimulated phosphoinositol turnover and enhances forskolin-stimulated cAMP increases in CNS tissues. Modulates IKK activation, suppressing the NF-κB signaling pathway. Blocks proliferation of human leukemia and multiple myeloma cells. Exhibits anti-inflammatory activity.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Mourey et al (1992) [3H]Noscapine binding sites in brain: relationship to indoleamines and the phosphoinositide and adenylyl cyclase messenger systems. Mol.Pharmacol. 42 619. PMID: 1331753.
Mahmoudian and Mojaverian (2001) Effect of noscapine, the antitussive opioid alkaloid, on bradykinin-induced smooth muscle contraction in the isolated ileum of the guinea-pig. Acta Physiol.Hung. 88 231. PMID: 12162581.
Landen et al (2002) Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 62 4109. PMID: 12124349.
Sung et al (2010) Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-κB signaling pathway. Cancer Res. 70 3259. PMID: 20354190.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Noscapine hydrochloride, supplier, Bradykinin, antagonists, tubulin, inhibitors, induces, apoptosis, B1, B2, Receptors, Tau, Microtubules, Mitosis, antitumor, activity, HCl, opioid, alkaloid
Find multiple products by catalog number
New Products in this Area
Synthetic version of amylin (Cat. No. 3418)SB 706375
High affinity, non-peptide UT receptor antagonistPG 106
Selective MC3 receptor antagonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.